Cancer Therapy News and Research

RSS

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT-, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer.

29 Oct 2013

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

A self-directed walking program shows promise in easing joint stiffness in older women who experienced these symptoms while taking aromatase inhibitor therapy for breast cancer, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Study confirms the "seed and soil" theory of metastasis

Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body - so-called disseminated tumor cells - are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head and neck squamous cell carcinoma cells, which remain dormant when lodged in bone marrow but rapidly form tumors when they make their way into the lungs.

28 Oct 2013

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.

25 Oct 2013

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine for its October 24, 2013 issue.

25 Oct 2013

MIT researchers design stealth drug delivery system to attack TNBC cells

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

25 Oct 2013

Rice University research reveals 3-way genetic switch for cancer metastasis

Cancer researchers from Rice University have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The study found that the on-off switch's dynamics also allows a third choice that lies somewhere between "on" and "off." The extra setting both explains previously confusing experimental results and opens the door to new avenues of cancer treatment.

25 Oct 2013

"One-two punch" disables tumors' defenses

An aggressive form of breast cancer known as "triple negative" is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs.

25 Oct 2013

Thomas Jefferson University’s interactive program discusses pros and cons of prostate cancer treatment

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program developed by Thomas Jefferson University researchers, more patients choose active surveillance over therapy, according to research being presented Wednesday (October 23rd) at the Society for Medical Decision Making annual meeting in Baltimore, Maryland.

24 Oct 2013

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Patient assistance programs can help breast cancer patients meet a variety of needs that can interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments, according to a study published recently in the online edition of the Journal of Oncology Practice.

24 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.

23 Oct 2013

Risk for breast cancer: Key prevention awareness tips for young women

Breast cancer prevention needs to become a shared conversation among women of all ages as it can strike at any age, and is generally more aggressive when diagnosed in women under the age of 50. With hopes to spark that discussion, Isabelle Mercier, PhD, a research assistant professor at University of the Sciences, compiled some key prevention awareness tips for young women.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

Scientist receives NIH New Innovator Award to design innovative approaches for cancer treatment

Derek Taylor, PhD, a member of the Case Western Reserve School of Medicine, has been awarded the prestigious New Innovator Award by the National Institutes of Health (NIH).

22 Oct 2013

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st.

18 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

18 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

Cancer Therapy News and Research

VisionGate's Cell-CT platform can detect lung cancer in sputum samples with high specificity

Self-directed walking program shows promise in easing joint stiffness in older breast cancer patients

Study confirms the "seed and soil" theory of metastasis

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

MIT researchers design stealth drug delivery system to attack TNBC cells

Rice University research reveals 3-way genetic switch for cancer metastasis

"One-two punch" disables tumors' defenses

Thomas Jefferson University’s interactive program discusses pros and cons of prostate cancer treatment

Patient assistance programs help breast cancer patients to learn more about adjuvant therapy

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

Risk for breast cancer: Key prevention awareness tips for young women

Study opens doors to novel treatments for aggressive brain cancer

Scientist receives NIH New Innovator Award to design innovative approaches for cancer treatment

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News